Advertisement
Home Tags Human Papillomavirus (HPV)

Tag: Human Papillomavirus (HPV)

Multilevel

Multilevel Interventions May Boost HPV Vaccination Rates

0
Improvements in initiation and completion extend beyond conclusion of the intervention
Nonwhite

Race, Insurance Status Linked to Lower Cancer Survival

0
Reduced survival seen in HPV-associated head and neck cancer for nonwhite, uninsured patients
Receipt of one

Single Dose of HPV Vaccine May Cut Preinvasive Cervical Disease

0
Risk for preinvasive cervical disease decreased with one, two, three vaccine doses at age 15 to 19 years
Methodological problems and study limitations for trials of the human papillomavirus vaccine create uncertainty about its ability to prevent cervical cancer in the long term

Whether HPV Vaccination Will Prevent Cervical Cancer Unclear

0
Review highlights limitations of trial design; additional research needed to address uncertainties
Misinformation in the Danish media between 2013 and 2016 led to a 50.4 percent drop in human papillomavirus vaccinations among girls in Denmark

Vaccine Program Recovery Difficult After Public Scares

0
Misinformation is threat to resilience of vaccination programs globally, authors say
For patients with oropharynx cancer

Mortality Risk in Oropharynx Cancer Varies Based on HPV Status

0
Patients with OPC with HPV-negative tumors have increased risk for head and neck cancer mortality
From 2013 to 2018

CDC: Young Adults Who Ever Received HPV Vaccine on the Rise

0
2013 to 2018 saw increase in percentage having received one or more doses, recommended number of doses
Only one in four patients with sinonasal squamous cell carcinoma is tested for human papillomavirus

Routine HPV Testing May Be Warranted for Sinonasal Cancers

0
HPV-positive sinonasal squamous cell carcinoma associated with improved overall survival
U.S. women who have received one dose of human papillomavirus vaccine have similar protection as women who have received two or three doses

Protection Similar With Single, Multiple HPV Vaccine Doses

0
Infection with HPV 6, 11, 16, 18 less prevalent among women receiving one, two, three doses of HPV vaccine
Extending the current human papillomavirus (HPV) vaccination program to age 45 years is expected to produce small additional reductions in HPV-associated diseases with high additional costs

Extending HPV Vaccination to Age 45 Provides Small Additional Benefit

0
Vaccinating women and men to age 45 years predicted to have high costs per QALY gained